These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16416553)

  • 41. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.
    Dowsett M; Smith IE; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G; A'Hern R
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1024s-1030s. PubMed ID: 16467120
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hemicentral retinal artery occlusion in a breast cancer patient using anastrozole.
    Karagöz B; Ayata A; Bilgi O; Uzun G; Unal M; Kandemir EG; Ozgün A; Türken O
    Onkologie; 2009 Jul; 32(7):421-3. PubMed ID: 19556821
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Endocrine options for breast cancer treatment: looking beyond tamoxifen.
    Watanabe T; Sonoo H
    Breast Cancer; 2000; 7(4):345-9. PubMed ID: 11114863
    [No Abstract]   [Full Text] [Related]  

  • 44. Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer.
    Schwartzberg LS; Cobb P; Senecal F; Henry D; Kulig K; Walker MS; Houts AC; Stepanski EJ
    Breast; 2009 Apr; 18(2):78-83. PubMed ID: 19342237
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer: methodologic issues.
    Winquist E; Bramwell V; Vandenberg T
    J Clin Oncol; 2002 Sep; 20(17):3748-9; author reply 3749-50. PubMed ID: 12202679
    [No Abstract]   [Full Text] [Related]  

  • 46. Critique of survival update analysis from two phase III anastrozole clinical trials.
    Buzdar AU
    Ann Surg Oncol; 1999 Dec; 6(8 Suppl):8S-11S. PubMed ID: 10619453
    [No Abstract]   [Full Text] [Related]  

  • 47. Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer.
    Toi M; Yamashiro H; Tsuji W
    Breast Cancer; 2009; 16(3):207-18. PubMed ID: 19259765
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anastrozole versus progestins/tamoxifen.
    Beat T
    Eur J Cancer; 2002 Nov; 38 Suppl 6():S49-51. PubMed ID: 12409073
    [No Abstract]   [Full Text] [Related]  

  • 49. A review of the BIG results: the Breast International Group 1-98 trial analyses.
    Doughty JC
    Breast; 2008 Jan; 17 Suppl 1():S9-S14. PubMed ID: 18279765
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Has the time come for genomic tests to guide the use of adjuvant chemotherapy in node-positive breast cancer?
    Azim HA
    Ann Oncol; 2015 Aug; 26(8):1521-3. PubMed ID: 26025966
    [No Abstract]   [Full Text] [Related]  

  • 51. Review of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer.
    Needleman SJ; Tobias JS
    Expert Rev Anticancer Ther; 2008 Dec; 8(12):1871-81. PubMed ID: 19046107
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
    Delea TE; El-Ouagari K; Karnon J; Sofrygin O
    Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hot flashes may be a good sign in women taking tamoxifen.
    Mayo Clin Womens Healthsource; 2007 Nov; 11(11):3. PubMed ID: 17898683
    [No Abstract]   [Full Text] [Related]  

  • 54. Prescribing extended adjuvant letrozole.
    Gelmon K
    Breast; 2007 Oct; 16(5):446-55. PubMed ID: 17544670
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
    Collins B; Mackenzie J; Stewart A; Bielajew C; Verma S
    Psychooncology; 2009 Aug; 18(8):811-21. PubMed ID: 19085975
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Breast cancer drug shows promise for some survivors.
    Levenson D
    Rep Med Guidel Outcomes Res; 2003 Oct; 14(21):7-9. PubMed ID: 14628765
    [No Abstract]   [Full Text] [Related]  

  • 57. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Interview with Prof. Dr. Wolfgang Eiermann. Which women need a medicamentous breast cancer prophylaxis?].
    Eiermann W
    MMW Fortschr Med; 2003 Dec; 145(50):8. PubMed ID: 14963963
    [No Abstract]   [Full Text] [Related]  

  • 59. New alternative to tamoxifen.
    Harv Womens Health Watch; 2002 Jul; 9(11):7. PubMed ID: 12138025
    [No Abstract]   [Full Text] [Related]  

  • 60. Anastrozole as a preventive agent in breast cancer.
    Thornton H
    Lancet; 2003 May; 361(9372):1911-2. PubMed ID: 12788605
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.